Community-acquired pneumonia (CAP) is the leading cause of death among infectious
diseases and an important health problem, having considerable implications for healthcare …

Objective: To review the spectrum of activity, efficacy, safety, and role in therapy of all
antibiotics and related biologics approved by the Food and Drug Administration (FDA) in the …

Background. Increasing antimicrobial resistance among pathogens causing complicated
intra-abdominal infections (cIAIs) supports the development of new antimicrobials …

Background Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can
be administered intravenously or orally, reaches high concentrations in pulmonary tissues …

Very old (aged≥ 80 years) adults constitute an increasing proportion of the global
population. Currently, this subgroup of patients represents an important percentage of …

Ceftaroline fosamil, the prodrug of the active metabolite, ceftaroline, is a new, broad-
spectrum cephalosporin recently approved in the USA for the treatment of acute bacterial …

Background The number of antibiotics in the pipeline targeting Gram-positive pathogens has
increased in recent years. Aims This narrative review aims to provide a summary of existing …

Background Community-acquired bacterial pneumonia (CABP) is a leading cause of
morbidity and mortality, and treatment recommendations, each with specific limitations, vary …

Ceftaroline has been approved for acute bacterial skin infections and community-acquired
bacterial pneumonia. Limited clinical experience exists for use outside these indications …

ABSTRACT Introduction Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream
infection (BSI) is a major issue in healthcare, since it is often associated with endocarditis or …